Peginterferon ??-2a and ribavirin versus peginterferon ??-2a monotherapy in early virological responders and peginterferon ??-2a and ribavirin versus peginterferon ??-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in na??ve patients with chronic hepatitis C

Autor:	S Gentile, Salvatore Zaru, A. Barlattani, Franco Bandiera, Antonio Grieco, Mario Angelico, Pierluigi Tarquini, Beate Koehler-Horst, Giampaolo Pilleri, Laura Ponti, Z. Rossi, Paola Piccolo, Paolo Guarascio, Francesco Soccorsi, Giuseppe Forlini, Simona Francioso, Francesco Angelico, Orazio Sorbello, Luigi Demelia, Roberto Della Vecchia
Rok vydání:	2008
Předmět:	medicine.medical_specialty Hepatology business.industry Ribavirin Gastroenterology Amantadine virus diseases Peginterferon alpha-2a Virological response Therapy naive chemistry.chemical_compound chemistry Chronic hepatitis Internal medicine Immunology medicine Viral disease business Peginterferon alfa-2a medicine.drug
Zdroj:	European Journal of Gastroenterology & Hepatology. 20:680-687
ISSN:	0954-691X
DOI:	10.1097/meg.0b013e3282f5196c
Popis:	ObjectiveThe objective of this study was to compare the efficacy of anti-hepatitis C virus (anti-HCV) treatment schedules on the basis of an early virological response (EVR), defined as undetectable serum HCV-RNA (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::206f8f41eee40628fde989023388c2e8 https://doi.org/10.1097/meg.0b013e3282f5196c Zobrazit plný text záznamu